Telix Pharmaceuticals Ltd: Telix Completes TLX250-CDx (Zircaix) BLA Submission
Telix Pharmaceuticals Ltd: Update - Application for quotation of securities - TLX
Telix Pharmaceuticals Ltd: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
Telix Pharmaceuticals Ltd: Response to ASX Query
Telix Pharmaceuticals Ltd: Telix Submits NDA for New Prostate Cancer Imaging Agent
Telix Pharmaceuticals Ltd: Becoming a substantial holder from MUFG
Telix Pharmaceuticals Ltd: Telix Results of Annual General Meeting
Telix Pharmaceuticals Ltd: Telix Annual General Meeting - Presentation
Telix Pharmaceuticals Ltd: Telix Annual General Meeting - Chairman and CEO Addresses
Telix Pharmaceuticals Ltd: Becoming a substantial holder
Telix Pharmaceuticals Ltd: Becoming a substantial holder
Telix Pharmaceuticals Ltd: Becoming a substantial holder from MS
Telix Pharmaceuticals Ltd: Becoming a substantial holder
Telix Pharmaceuticals Ltd: Becoming a substantial holder
Telix Pharmaceuticals Ltd: Telix Completes Proof-of-Concept Study for Alpha Therapy
Telix Pharmaceuticals Ltd: Notification regarding unquoted securities - TLX
Telix Pharmaceuticals Ltd: Cleansing Notice
Telix Pharmaceuticals Ltd: Application for quotation of securities - TLX
Telix Pharmaceuticals Ltd: Telix has Filed Registration Statement for Proposed US IPO
Telix Pharmaceuticals Ltd: Telix Reports Q1 2024 Financial Performance
No Data